NEW ORLEANS — Initial results from the ALTITUDE study suggest that suprachoroidal RGX-314 is well tolerated in the treatment of diabetic retinopathy, according to a speaker here.
During a sponsored media breakfast at the American Academy of Ophthalmology meeting, Arshad Khanani, MD, presented initial results from the phase 2 ALTITUDE study investigating RGX-314 (Regenxbio), looking at the study’s first cohort of patients receiving 2.5 × 1011 genomic copies per eye of RGX-314 compared with an observational control group. had a two-step or greater improvement in visual acuity. Four